Neurodegenerative Disorder Demand is Expanding at a CAGR of 6.7% to Reach US$ 6.8 Billion by 2033 | Report Fact.MR

The neurodegenerative disorders market in US is expected to grow strongly and is projected to grow at a CAGR of 6.7% and be valued at USD 1.1 billion by 2033. A growing aging population is believed to contribute to the spread of neurodegenerative diseases. Increasing funding for research projects focused on neurodegenerative diseases and early detection of neurological diseases is expected to contribute to market expansion in the country.

According to an analysis by Fact.MR, the global neurodegenerative diseases market is poised to grow in size and expected value. Growing from USD 3.6 billion in 2023 to a significant USD 6.8 billion by 2033. This growth is expected to support continued growth in global neurodegenerative disease treatment revenue, which is expected to grow by 6.7% between 2023 and 2033.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8634

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

Bharat Heavy Electricals Limited
Mitsubishi Heavy Industries
IHI Corporation
Babcock & Wilcox
Larsen And Toubro
Hitachi zosen corporation
General Electrics
Buhman Macatec
Alfa Laval
Godrej and Boyce
Sieco Engineers
Acme Engineering Products
Paul Mueller Company
Karbonsan Pressure Vessels
Trading Co.

Neurodegenerative diseases, a class of diseases characterized by progressive degeneration of the nervous system, have long presented significant challenges to health care providers and researchers. Diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS) affect millions of people worldwide and are associated with significant human suffering and high healthcare costs. However, in recent years there have been significant breakthroughs in the treatment of neurodegenerative diseases, offering new hope to patients and their families.

𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐧𝐝 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬

One of the most important advances in the treatment of neurodegenerative diseases is the transition to precision medicine. Scientists are now able to better understand the genetic and molecular background of these diseases, which allows for more targeted and individualized treatment. This shift from a one-size-fits-all approach to tailored treatment has resulted in better outcomes for patients and fewer side effects.

𝐃𝐢𝐬𝐞𝐚𝐬𝐞-𝐌𝐨𝐝𝐢𝐟𝐲𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬

Traditionally, many treatments for neurodegenerative disorders have focused on managing symptoms rather than treating the underlying causes of these diseases. However, recent breakthroughs have paved the way for disease-modifying therapies that aim to slow or even halt the progression of these diseases. For Alzheimer's disease, for example, drugs targeting beta-amyloid and tau proteins are showing promise in clinical trials as drugs that can change the course of the disease.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Many companies operating in the global neurodegenerative disorders market invest heavily in research and development. Major players often use strategies such as mergers, acquisitions and product line extensions. Market leaders are also adopting innovative approaches, including new developments and unique marketing strategies, to increase their market presence.

Amylyx Pharmaceuticals announced in a major announcement in September 2022 that the FDA has approved RELYVRIO (containing sodium phenylbutyrate). . and taurorsodiol) as a treatment for adults with amyotrophic lateral sclerosis (ALS).

In addition, the US subsidiary of the parent company, Mitsubishi Tanabe Pharma America, signed a license and supply agreement with Aquestive Therapeutics in January 2021. Inc. to secure the rights to Riluzole Oral Film in the United States, a treatment specifically designed for ALS.

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐍𝐞𝐮𝐫𝐨𝐝𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By Diagnosis & Treatment :
Diagnosis
Inpatient
Outpatient
Treatment
Drugs
Riluzole
Edaravone
Therapy
Breathing & Feeding Care
Physical Therapy
Occupational Therapy
Speech Therapy
Assistive Technology Devices
Brain-computer Interfaces
Human-computer Interfaces
Speech Generating Devices
Communication Boards and Symbol Devices
Other Assistive Devices

By Indication :
Amyotrophic Lateral Sclerosis (ALS)
Locked-in Syndrome (LIS)

By Distribution Channel :
Hospitals Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
e-Commerce
Supermarkets

By Service Provider :
Hospitals
Specialty Clinics
Rehabilitation Centers
Home Care Settings
Nursing Care Settings
Diagnostic Centers

By Region :
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://www.factmr.com/report/pressure-vessels-market

The market of neurodegenerative disorders is currently witnessing a phase of change with breakthroughs in the treatment of the disease. These developments offer new hope to patients and their families who have long battled the devastating effects of these diseases. As scientists continue to unravel the mysteries of these diseases, it is increasingly likely that new and more effective treatments will emerge that will ultimately change the landscape of treatment for neurodegenerative disorders. These innovations are a sign of hope in the quest to improve the quality of life and possible cures for those suffering from these debilitating diseases.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.